1. Introduction

Biotech licensing disputes are legal conflicts arising when parties disagree over the grant, scope, interpretation, performance, ownership, enforcement, or termination of a licence involving biotechnology-related intellectual property, technology, biological materials, or commercial rights.

Biotechnology licensing is particularly complex because it can involve several overlapping legal interests:

Patents covering genes, proteins, microorganisms, vaccines, diagnostic methods, biologic medicines, and genetic engineering.

Know-how, trade secrets, manufacturing protocols, cell lines, and proprietary research data.

Research and development agreements between universities, biotechnology companies, pharmaceutical manufacturers, and research institutions.

Rights to clinical-trial data, regulatory submissions, royalties, sublicensing, and commercialisation.

Access to biological resources, genetic materials, and associated traditional knowledge.

A dispute may arise when a licensee manufactures a product outside the permitted field, a licensor claims unpaid royalties, a patent is challenged as invalid, or the parties disagree about who owns an invention developed collaboratively.

Central legal principle: A biotechnology licence is a contractual arrangement, but its enforceability depends on the underlying intellectual-property rights, applicable regulatory law, competition law, and the jurisdiction in which the dispute arises.

This explanation focuses primarily on Indian law, with important United States, United Kingdom, and European cases that provide comparative guidance. The relevance of each foreign judgment in India depends on Indian legislation and precedent.

2. Meaning and principal types of biotech licensing disputes

Kanaph Therapeutics — IPOX

A. Patent licensing disputes

Disagreements over patent ownership, validity, infringement, claim scope, exclusivity, territorial coverage, and whether a licensed patent actually covers the product being commercialised.

Pharmaceutical Detergents

B. Manufacturing and technology-transfer disputes

Conflicts over access to cell lines, biological materials, production protocols, quality standards, technical assistance, process improvements, and technology-transfer milestones.

Meet the Chiba Team | AGC Biologics

C. Royalty and financial disputes

Disputes about royalty calculations, minimum payments, milestone fees, audit rights, net sales, deductions, sublicensing revenue, and unpaid consideration.

Scientist analysing dna helix

D. Research ownership and data disputes

Conflicts over jointly developed inventions, improvements, research results, confidential data, background intellectual property, and rights to use clinical or experimental findings.

Other important categories include unauthorised sublicensing, breach of confidentiality, termination of exclusive licences, disputes over regulatory approvals, competing licences, and alleged misuse of biological resources.

3. Legal framework governing biotech licensing disputes in India

The governing law depends on the subject matter of the licence and the nature of the alleged breach.

Additional requirements may arise under the Drugs and Cosmetics Act, 1940, applicable rules, clinical-trial regulations, environmental legislation, and laws governing export controls or access to biological materials.

A. Patent licensing under the Patents Act, 1970

Sections 68 and 69 are particularly relevant to written patent licences and the registration of documents concerning patent interests. Section 107 permits specified grounds of patent revocation to be raised as defences in infringement proceedings, while Section 108 provides remedies for patent infringement.

Section 140 addresses certain restrictive conditions in patent-related contracts. Section 84 governs compulsory licensing on specified grounds, including unmet public requirements, unaffordable pricing, and failure to work the patent in India, subject to statutory requirements.

An important distinction is that a contractual licence does not automatically establish that the underlying patent is valid or that every licensed use is lawful.

B. Contractual enforcement

Under the Indian Contract Act, a biotech licensing agreement should identify the licensed rights, consideration, duration, territory, permitted uses, obligations of both parties, and consequences of breach.

Section 73 addresses compensation for loss or damage caused by breach of contract. Section 74 concerns reasonable compensation where a sum is stipulated or a penalty is provided for breach, subject to its terms.

For example, if a pharmaceutical company receives a licence to manufacture a biologic medicine but fails to pay agreed royalties, the licensor may seek contractual remedies, an account of amounts due, and appropriate interim or final relief.

The outcome depends on the agreement, evidence, applicable statutory provisions, and available defences.

4. Important case laws on biotech licensing disputes

The following judgments illustrate how courts address ownership, royalty obligations, licence scope, patent validity, research rights, and compulsory licensing.

Case 1: Monsanto Technology LLC v. Nuziveedu Seeds Ltd.

Supreme Court of India · 2019 · Biotechnology and agricultural licensing

Facts: Monsanto licensed technology relating to genetically modified Bt cotton to Indian seed companies. The relationship involved sublicensing arrangements, trait fees, and disputes concerning the protection of the underlying technology under Indian patent law.

Legal issues:

Whether the technology and associated inventions were protected by enforceable patents.

Whether the licensing arrangements could continue in the manner claimed by the parties.

Whether questions about patentability and the interpretation of biotechnology-related rights required detailed adjudication.

Decision and significance: The Supreme Court set aside the Delhi High Court's summary determination and remanded the matter for consideration of the issues on their merits. The decision should not be read as a final declaration that every disputed Monsanto patent or licensing restriction was valid.

Competition Commission of India

Legal principle: A biotechnology licence dispute may turn on the nature and validity of the underlying intellectual property, not merely on the wording of the contract.

Practical application: Agreements concerning genetically modified seeds should expressly address trait fees, permitted seed varieties, sublicensing, regulatory compliance, technology improvements, and the consequences of patent invalidation.

Case 2: Bayer Corporation v. Union of India (Bayer–Natco compulsory licensing litigation)

Intellectual Property Appellate Board · 2013; Bombay High Court proceedings followed

Facts: Bayer held a patent relating to sorafenib tosylate, a medicine used to treat certain cancers. Natco sought permission to manufacture and sell the medicine under a compulsory licence, arguing that the statutory conditions were satisfied.

Issues: Whether the requirements of Section 84 of the Patents Act were met, including reasonable public requirements, affordability, and working of the invention in India.

Decision: The Intellectual Property Appellate Board upheld India's first compulsory licence granted under Section 84, while modifying the royalty rate payable to Bayer. Subsequent litigation addressed related issues, including the scope of research and regulatory-use exceptions.

WIPO+1

Relevance to biotech licensing: Although this was a pharmaceutical patent dispute rather than a classic privately negotiated biotech licence, it demonstrates that patent exclusivity is subject to statutory limits.

Legal principle: Contractual exclusivity cannot eliminate statutory compulsory-licensing mechanisms where their legal requirements are satisfied.

Case 3: Novartis AG v. Union of India

Supreme Court of India · (2013) 6 SCC 1

Facts: Novartis sought patent protection for a crystalline form of imatinib mesylate, a medicine used in cancer treatment.

Issue: Whether the claimed invention satisfied the patentability requirements, particularly Section 3(d) of the Patents Act.

Decision: The Supreme Court upheld the rejection of the patent application, finding that the claimed form did not satisfy the applicable statutory test for enhanced efficacy.

United Nations

Importance for licensing disputes: A licence to exploit a patent or patent application may have limited commercial value if the underlying rights are refused, invalidated, or narrower than the parties assumed.

Practical lesson: Licensing agreements should distinguish between granted patents, pending applications, know-how, and independently protectable trade secrets. They should also specify what happens if a patent is refused or revoked.

Case 4: Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc.

United States Supreme Court · 563 U.S. 776 (2011)

Facts: A Stanford researcher worked with Cetus, later acquired by Roche, on technology used in HIV testing. Competing agreements purported to establish rights in the researcher's inventions.

Issue: Whether federally funded research automatically vested ownership in Stanford under the Bayh–Dole Act, overriding the researcher's earlier assignment of rights.

Decision: The US Supreme Court held that the Bayh–Dole Act does not automatically transfer title to federally funded inventions to a university or contractor. Ownership remained subject to the applicable assignment arrangements and general patent-law principles.

Justia U.S. Supreme Court Center+1

Legal principle: Funding a research project does not, by itself, settle every question of invention ownership.

Application: Universities, research hospitals, and biotech companies should ensure that employee agreements, visiting-researcher contracts, sponsored-research agreements, and external collaboration agreements contain consistent and properly executed intellectual-property assignments.

Case 5: City of Hope National Medical Center v. Genentech, Inc.

California Supreme Court · 43 Cal. 4th 375 (2008)

Facts: City of Hope and Genentech entered into a research and commercialisation arrangement involving recombinant DNA technology and the development of human proteins. The parties disputed royalty obligations associated with products and third-party licensing arrangements.

Issue: Whether Genentech's contractual obligations required it to share additional royalties or settlement proceeds and whether it had breached the agreement.

Decision: The California Supreme Court considered the contractual and fiduciary-duty issues and rejected the proposition that the parties' commercial relationship automatically created the fiduciary obligations asserted in the case. The written contract remained central to determining the parties' rights.

California Supreme Court Resources

Legal principle: A research collaboration does not automatically create fiduciary duties beyond those established by the agreement and applicable law.

Application: A biotech licence should specify how third-party licence revenue, patent-infringement settlements, sublicensing payments, and royalties are calculated and reported. It should also establish audit rights and expressly identify any fiduciary or agency relationship intended by the parties.

Case 6: MedImmune, Inc. v. Genentech, Inc.

United States Supreme Court · 549 U.S. 118 (2007)

Facts: MedImmune licensed biotechnology-related patent rights from Genentech but disputed whether the relevant patent was valid and infringed. MedImmune continued making royalty payments while challenging the patent.

Issue: Whether a licensee had to breach or terminate its licence before seeking a judicial declaration that the patent was invalid, unenforceable, or not infringed.

Decision: The US Supreme Court held that the licensee could seek declaratory relief without first terminating the agreement or deliberately breaching it, provided the constitutional requirements for a live controversy were met.

Legal Information Institute

Legal principle: A licensee's continued compliance with a licence does not necessarily prevent it from challenging the underlying patent in court.

Application: This case is important when drafting provisions concerning patent challenges, continued royalty payments, termination rights, and dispute-resolution procedures. Its procedural holding arises under US law and does not automatically govern Indian proceedings.

Case 7: Madey v. Duke University

US Court of Appeals for the Federal Circuit · 307 F.3d 1351 (2002)

Facts: A former professor alleged unauthorised use of patented laser technology at Duke University after leaving the institution.

Issue: Whether the university's research activities were protected by the US experimental-use defence.

Decision: The appellate court rejected the broad application of the experimental-use defence on the facts, explaining that university research can further institutional business interests and therefore does not automatically escape patent liability.

Justia Law

Importance for biotechnology: Research institutions cannot assume that laboratory use of licensed or patented genetic engineering, sequencing, or diagnostic technologies is automatically exempt from patent restrictions.

Practical lesson: Research licences should clearly define permitted experiments, internal research, clinical validation, commercial development, and publication rights.

5. Comparative case-law summary

6. Common grounds for biotech licensing disputes

A. Breach of licence scope

A licence may authorise a company to use a patented process for diagnostic research but prohibit commercial manufacturing. If the licensee starts selling diagnostic kits without the required commercial rights, the licensor may allege breach of contract and, where applicable, patent infringement.

The critical question is whether the conduct exceeds the rights actually granted.

B. Royalty underpayment and accounting disputes

Royalty disputes often arise from ambiguity about:

Whether royalties apply to gross sales or net sales.

Whether combination products attract royalties on the whole product or only the licensed component.

Whether sublicensing revenue is included.

Whether royalties continue after a patent expires.

Whether milestone payments become due upon regulatory approval, first commercial sale, or another event.

The parties should agree on consistent accounting rules and permit reasonable independent audits.

C. Ownership of jointly developed inventions

In biotechnology, improvements can emerge during manufacturing, testing, or clinical development. The original licensor may claim ownership of improvements based on its background technology, while the licensee may claim ownership because its employees independently developed them.

A sound agreement distinguishes:

Background IP: Rights owned or controlled before the collaboration.

Foreground IP: Rights created during the project.

Improvements: Modifications, optimisations, and new inventions.

Data and materials: Experimental results, biological samples, cell lines, and research records.

Ownership should be determined by the agreed contractual allocation and applicable law, rather than by vague references to technology developed “in connection with” the project.

D. Breach of confidentiality and trade secrets

Biotech licences may disclose cell-culture conditions, fermentation parameters, protein-purification methods, genetic constructs, or manufacturing protocols.

Unauthorised disclosure to a competitor can cause commercial damage even where the disclosed information is not patented. Remedies may include contractual damages, confidentiality injunctions, and other relief available under the governing law.

The agreement should identify confidential information, restrict access to authorised personnel, establish permitted disclosures, and provide post-termination obligations.

E. Unauthorised sublicensing

An exclusive licensee may attempt to transfer rights to an affiliate or third-party manufacturer without obtaining the licensor's approval.

Whether this is a breach depends on the sublicensing clause, any statutory requirements, and the nature of the transfer. Agreements should state whether sublicences require prior written consent, what minimum terms they must contain, and whether the primary licensee remains liable for the sublicensee's conduct.

F. Regulatory and performance failures

A licence may require the licensee to meet development milestones, obtain regulatory approvals, comply with good manufacturing practices, or achieve minimum sales.

A dispute can arise when approvals are delayed, a batch fails quality standards, or the licensor does not provide agreed technical assistance. The contract should distinguish delays caused by a party's breach from delays caused by regulators, supply disruptions, or other events outside reasonable control.

7. Remedies available in biotech licensing disputes

The appropriate remedy depends on whether the claim is contractual, patent-related, confidentiality-related, regulatory, or competition-related.

1. Damages and unpaid royalties

Compensation for provable contractual losses, unpaid royalties, and other recoverable amounts. Indian Contract Act Sections 73 and 74 are relevant to contractual compensation.

2. Injunctions

A court may restrain unauthorised use, disclosure, or infringement where the applicable legal requirements are met. Relief is not automatic merely because a licence has been breached.

3. Termination or suspension

Termination may be available for a material breach, failure to cure, or another agreed trigger. Suspension should follow the contract and applicable law.

4. Accounting and audit

An audit can establish sales figures, sublicensing receipts, royalty deductions, and the amounts actually payable.

5. Arbitration or negotiated settlement

The parties may resolve technical and commercial disagreements through negotiation, mediation, or arbitration when an enforceable arbitration agreement covers the dispute.

Can a court order specific performance?

Potentially, but not in every case. The Specific Relief Act, 1963, as amended, governs specific performance in India, subject to its statutory restrictions. A court may be reluctant to compel continuing cooperation where performance requires sustained personal services, complex scientific collaboration, or constant supervision. An injunction, damages, or a tailored contractual remedy may be more appropriate.

Patent infringement claims and patent-validity questions also require separate consideration; the existence of an arbitration clause does not automatically make every patent-related issue arbitrable.

8. Arbitration and jurisdiction

Biotech licensing agreements frequently involve parties in different countries. A dispute may therefore raise questions about the governing law, arbitration seat, court jurisdiction, interim relief, and enforceability of an award.

A well-drafted dispute-resolution clause should identify:

Governing law of the agreement.

Arbitration rules and seat, if arbitration is selected.

Number and method of appointment of arbitrators.

Confidentiality and treatment of technical evidence.

Availability of urgent interim relief.

Treatment of patent validity, infringement, and regulatory questions that may require proceedings before a competent court or authority.

Under the Arbitration and Conciliation Act, 1996, Sections 9 and 17 address interim measures in their respective judicial and arbitral contexts, while Section 34 provides grounds for setting aside certain domestic arbitral awards. International commercial arbitration and enforcement of foreign awards involve additional statutory rules.

Important distinction: A dispute about whether royalties are payable under a contract is not necessarily the same as a dispute about whether a patent is valid against the world. The nature of the relief sought can materially affect the appropriate forum.

9. How courts should analyse a biotech licensing dispute

A systematic legal analysis generally follows these steps.

Identify the licensed subject matter.

Determine whether the dispute concerns a patent, know-how, biological material, software, research data, or a combination of rights.

Establish ownership and authority to license.

Examine patent records, assignments, employee agreements, research contracts, and sublicensing authority. Under Section 68 of the Indian Patents Act, patent licences must satisfy the applicable writing and execution requirements.

IndiaCode

Interpret the agreement.

Examine the grant clause, exclusivity, territory, permitted field of use, royalty provisions, milestones, and termination terms.

Assess validity and infringement separately.

Consider whether the patent is valid, whether the relevant claims cover the activity, and whether a statutory exception or contractual defence applies. Section 107 permits patent revocation grounds to be raised as defences in infringement proceedings.

India Code

Determine the appropriate forum and remedy.

Assess contractual remedies, patent proceedings, arbitration, regulatory proceedings, and any competition-law issues.

10. Drafting safeguards to prevent future disputes

The best way to reduce biotech licensing litigation is to address the following matters expressly in the agreement.

Special care is necessary when licensing biological resources or genetic materials. Depending on the parties, material, and activity, the Biological Diversity Act, 2002, as amended, and applicable rules may impose separate access, approval, or benefit-sharing obligations. A private contract cannot displace mandatory statutory requirements.

11. Illustrative hypothetical dispute

Suppose an Indian biotechnology company receives an exclusive licence to manufacture a genetically engineered therapeutic protein. The agreement requires a 5% royalty on net sales and prohibits sublicensing without written consent.

Two years later, the licensee sublicenses manufacturing to a third party, excludes certain sales from its royalty statements, and claims that a key patent is invalid.

The licensor could potentially pursue:

Contractual claims for unpaid royalties and breach of the sublicensing clause.

An audit of sales and sublicensing records.

Injunctive relief, if the relevant legal tests are met.

Patent infringement remedies if the conduct exceeds the licence and the patent is enforceable.

Arbitration, if the agreement provides for it and the claims fall within its scope.

The licensee could respond by disputing the royalty calculations, contesting the alleged breach, raising applicable contractual defences, or challenging patent validity through an available legal procedure.

The court or tribunal would need to distinguish the contractual accounting issues from the patent-law issues. Neither the licensor's allegations nor the licensee's assertion of invalidity would, by itself, resolve the dispute.

12. Conclusion

Biotech licensing disputes sit at the intersection of contract law, patent law, commercial regulation, research governance, and competition law. The principal legal questions concern who owns the technology, what rights were granted, whether the parties complied with their obligations, and which remedies are legally available.

The Indian decisions in Monsanto v. Nuziveedu, Bayer v. Natco, and Novartis v. Union of India, together with the comparative judgments in Stanford v. Roche, City of Hope v. Genentech, and MedImmune v. Genentech, demonstrate different aspects of these problems. They should be applied according to their actual holdings and the law governing the particular dispute.

For legal research, the most useful next step is to examine biotech licensing dispute resolution and arbitration clauses, including how patent validity, royalty recovery, confidentiality, and termination claims are handled under Indian law.